- About TapImmune
- News & Media
- Contact Us
Phase I Trial analyses shows safety and positive immune response data SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in...
SEATTLE, June 2, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, and its institutional investors have reached an agreement whereby the institutional investors will have the option to exercise their short term warrants to provide the Company up to...